Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

Fig. 2

Sphingomyelin burden in liver tissue. The percent liver tissue area occupied by sphingomyelin is shown throughout the study during placebo or olipudase alfa treatment periods. Means are shown above and below the lines for the group crossing over to olipudase alfa from placebo and the olipudase alfa group, respectively. Liver tissue was obtained from biopsies at baseline, week 52, and week 104. Liver sphingomyelin burden was assessed by computer morphometry of high-resolution light microscopy imaging of stained tissue

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172